{"id":8,"date":"2024-10-13T10:23:03","date_gmt":"2024-10-13T10:23:03","guid":{"rendered":"http:\/\/localhost\/wordpress\/eg427\/?page_id=8"},"modified":"2026-02-09T12:52:17","modified_gmt":"2026-02-09T12:52:17","slug":"home","status":"publish","type":"page","link":"https:\/\/clinicaltrials.eg427.com\/es\/","title":{"rendered":"Home"},"content":{"rendered":"
\n
\n \"Hero\n <\/div>\n\n
\n
\n\n
EG110A-001-01<\/div>\n

Problemas de vejiga en personas con lesi\u00f3n de la m\u00e9dula espinal<\/h1>\n \n
\n

\u00a1Conoce m\u00e1s acerca del nuevo estudio cl\u00ednico EG110A-001-01!<\/p> <\/div> \n \n \n <\/div>\n <\/div>\n\n<\/div> \n\n

\n
\n \"Pattern\"\n <\/div>\n
\n \"Pattern\"\n <\/div>\n
\n \"Background\n <\/div>\n\n
\n
\n\n
\n
Acerca de<\/div>\n

\u00bfDe qu\u00e9 se trata el estudio?<\/h2>\n

Terapia EG110A<\/h4>\n \n
\n
\n

Este ser\u00e1 el primer estudio en humanos para EG110A \u2013 un producto de investigaci\u00f3n especialmente dise\u00f1ado y dirigido. <\/strong><\/p> <\/div>\n

\n

EG110A es un nuevo vector de terapia g\u00e9nica no multiplicante (es decir, transportador) dise\u00f1ado que proporciona un f\u00e1rmaco del estudio dirigido a c\u00e9lulas nerviosas espec\u00edficas cercanas a la m\u00e9dula espinal<\/strong> que controlan la vejiga.<\/p> <\/div>\n <\/div> \n <\/div>\n\n

\n \"\" <\/div>\n \n\n <\/div>\n <\/div>\n\n<\/div> \n\n\n
\n
\n
\n
\n
\n \"clinical-trial-research-lab\" <\/div>\n
Acci\u00f3n terap\u00e9utica propuesta<\/h5>\n
\n

Esta terapia tiene como objetivo bloquear se\u00f1ales nerviosas sensoriales espec\u00edficas de la vejiga para reducir los desencadenantes de las contracciones involuntarias de la vejiga y, de esta manera, reducir las p\u00e9rdidas de orina.<\/p> <\/div>\n <\/div>\n

\n
\n \"eg427-innovative-treatment-spinal-cord\" <\/div>\n
Efecto terap\u00e9utico propuesto<\/h5>\n
\n

Se espera que la acci\u00f3n del EG110A tenga una duraci\u00f3n prolongada, posiblemente durante varios a\u00f1os, despu\u00e9s de una sola administraci\u00f3n del tratamiento del estudio.<\/p> <\/div>\n <\/div>\n <\/div>\n

\n
\n \"\" <\/div>\n
\n El sitio del estudio le explicar\u00e1 m\u00e1s detalles sobre los posibles riesgos y beneficios y se detallar\u00e1n en el Consentimiento informado para este estudio. <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n\n
\n
\n \"Pattern\"\n <\/div>\n
\n \"Background\n <\/div>\n
\n \"Background\n <\/div>\n
\n
\n\n
\n \"\" <\/div>\n \n
\n
Participaci\u00f3n<\/div>\n

\u00bfQui\u00e9n puede unirse a este estudio?<\/h2>\n

Requisitos del participante <\/h4>\n \n
\n
\n

Este estudio se centrar\u00e1 en personas con vejiga neurog\u00e9nica, tambi\u00e9n llamada hiperactividad neurog\u00e9nica del detrusor,<\/strong> debido a una lesi\u00f3n de la m\u00e9dula espinal.<\/p> <\/div>\n

\n

Inscribiremos a participantes que vivan con fugas involuntarias de la vejiga<\/strong>, tambi\u00e9n llamada incontinencia urinaria incluso con los tratamientos actuales.<\/p> <\/div>\n <\/div> \n <\/div>\n\n <\/div>\n <\/div>\n<\/div>\n\n\n

\n
\n
\n
\n\n
\n
\n \"\" <\/div>\n
\n
Age<\/h5>\n

18-75 a\u00f1os<\/p>\n <\/div>\n <\/div>\n \n

\n
\n \"eg110a-clinical-study-patients\" <\/div>\n
\n
Gender<\/h5>\n

Todos los g\u00e9neros<\/p>\n <\/div>\n <\/div>\n \n

\n \"eg-427-fda-ind-clearance\" <\/div>\n
Lesi\u00f3n de la m\u00e9dula espinal<\/h5>\n
\n

La lesi\u00f3n de la m\u00e9dula espinal debe haber ocurrido en cualquier nivel por encima del sacro. La lesi\u00f3n debe tener al menos 12 meses de antig\u00fcedad antes de participar en este estudio.<\/p> <\/div>\n <\/div>\n

\n\n
\n
\n \"eg110a-clinical-study-patients\" <\/div>\n
\n
Gender<\/h5>\n

Todos los g\u00e9neros<\/p>\n <\/div>\n <\/div>\n \n

\n \"\" <\/div>\n
Incontinencia urinaria<\/h5>\n
\n

Los participantes deben tener incontinencia urinaria cr\u00f3nica (experimentar varios episodios de incontinencia urinaria por semana) y realizar un cateterismo intermitente limpio diario.<\/p> <\/div>\n <\/div>\n <\/div>\n \n <\/div>\n<\/div>\n\n\n

\n\n
\n \"\" <\/div>\n \n
\n \"\" <\/div>\n \n
\n\n
\n
\n \"Pattern\"\n <\/div>\n\n
Proceso<\/div>\n

\u00bfC\u00f3mo se administrar\u00e1 el medicamento?<\/h2>\n
Administraci\u00f3n<\/div>\n
\n

El medicamento del estudio se administrar\u00e1 como tratamiento \u00fanico mediante m\u00faltiples inyecciones en la pared de la vejiga. Esto es similar a lo que se hace con las inyecciones de toxina botul\u00ednica como BOTOX\u00ae en la vejiga (que es un tratamiento aprobado).<\/p> <\/div>\n \n

\n
\n
\n \"\" <\/div>\n
Anestesia<\/h5>\n
\n

El m\u00e9dico del estudio decidir\u00e1 junto con usted qu\u00e9 tipo de anestesia ser\u00e1 la mejor.<\/p> <\/div>\n <\/div>\n

\n
\n \"spinal-cord-injury-gene-therapy\" <\/div>\n
Hospitalizaci\u00f3n<\/h5>\n
\n

Se pedir\u00e1 al participante que permanezca una noche en el hospital despu\u00e9s de la administraci\u00f3n del f\u00e1rmaco del estudio para observaci\u00f3n.<\/p> <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n\n

\n \"neurogenic-bladder-treatment\" <\/div>\n \n <\/div>\n<\/div>\n\n\n
\n
\n \"Pattern\"\n <\/div>\n
\n \"Background\n <\/div>\n
\n \"\" <\/div>\n
\n
Duraci\u00f3n<\/div>\n

\u00bfCu\u00e1nto dura el estudio?<\/h2> \n\n
\n
\n \"\" <\/div>\n
\n
Duraci\u00f3n del estudio<\/div>\n
52 Semanas<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n \"\" <\/div>\n \t\n
\n \"\" <\/div>\n
\n \"\" <\/div>\n \n \n<\/div>\n\n\n
\n \n
\n\n
\n\n
\n
\n \"eg-427-clinical-trial-logo\" <\/div>\n <\/div>\n
\n
Contacta con nosotros<\/div>\n

Encontrar sitios de estudio<\/h2>\n
C\u00f3mo llegar a nosotros<\/div>\n
\n

Consulte la lista de sitios de estudio y su ubicaci\u00f3n a continuaci\u00f3n con su informaci\u00f3n de contacto.

\u00a1No dude en comunicarse directamente con los sitios del estudio si est\u00e1 interesado en obtener m\u00e1s informaci\u00f3n sobre este estudio!<\/p> <\/div>\n \n

\n
\n \"\" <\/div>\n
\n

Para obtener m\u00e1s informaci\u00f3n sobre estudios cl\u00ednicos, visite: www.clinicaltrials.gov<\/a><\/p> <\/div>\n <\/div>\n \n <\/div>\n\n <\/div>\n\n\n

\n \n
\n \"\" \n <\/div>\n
\n
\n
Centro Nacional de Rehabilitaci\u00f3n Rancho Los Amigos<\/div>\n\n
\n
\n \"Icon\"\n <\/div>\n
\n

7601 East Imperial Highway, Downey, Los Angeles, California<\/a><\/p> <\/div>\n <\/div>\n \n

\n
\n \"Icon\"\n <\/div>\n
\n Sandra Avina <\/div>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n 562-385-7048 <\/a>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n SAvina@ranchoresearch.org <\/a>\n <\/div>\n <\/div>\n
\n
UTHealth Houston \/ TIRR Memorial Hermann<\/div>\n\n
\n
\n \"Icon\"\n <\/div>\n
\n

1333, Moursund Street, Houston,
Texas<\/a><\/p> <\/div>\n <\/div>\n \n

\n
\n \"Icon\"\n <\/div>\n
\n Argy Stampas, MD, MS <\/div>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n 713-797-7162 <\/a>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n NeuroRecoveryResearch@memorialhermann.org <\/a>\n <\/div>\n <\/div>\n
\n
Sidney Kimmel Medical College<\/div>\n\n
\n
\n \"Icon\"\n <\/div>\n
\n

1025 Walnut Street, Suite 1112,
Philadelphia, Pennsylvania<\/a><\/p> <\/div>\n <\/div>\n \n

\n
\n \"Icon\"\n <\/div>\n
\n Oleksandr Kolesnikov <\/div>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n 215-459-0615 <\/a>\n <\/div>\n \n\n
\n
\n \"Icon\"\n <\/div>\n \n Oleksandr.Kolesnikov@jefferson.edu <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n Scroll right to see more locations <\/div>\n \n <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8","page","type-page","status-publish","hentry"],"yoast_head":"\nHome - Clinical trials | EG 427<\/title>\n<meta name=\"description\" content=\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinicaltrials.eg427.com\/es\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Home - Clinical trials | EG 427\" \/>\n<meta property=\"og:description\" content=\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinicaltrials.eg427.com\/es\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical trials | EG 427\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T12:52:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Map_updated.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1040\" \/>\n\t<meta property=\"og:image:height\" content=\"863\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"name\":\"Home - Clinical trials | EG 427\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#website\"},\"datePublished\":\"2024-10-13T10:23:03+00:00\",\"dateModified\":\"2026-02-09T12:52:17+00:00\",\"description\":\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#website\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"name\":\"Clinical trials | EG 427\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#organization\"},\"alternateName\":\"Clinical trials | EG 427\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#organization\",\"name\":\"Clinical trials | EG 427\",\"alternateName\":\"Clinical trials\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Design-6.png\",\"contentUrl\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Design-6.png\",\"width\":804,\"height\":1156,\"caption\":\"Clinical trials | EG 427\"},\"image\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Home - Clinical trials | EG 427","description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinicaltrials.eg427.com\/es\/","og_locale":"es_ES","og_type":"article","og_title":"Home - Clinical trials | EG 427","og_description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","og_url":"https:\/\/clinicaltrials.eg427.com\/es\/","og_site_name":"Clinical trials | EG 427","article_modified_time":"2026-02-09T12:52:17+00:00","og_image":[{"width":1040,"height":863,"url":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Map_updated.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clinicaltrials.eg427.com\/","url":"https:\/\/clinicaltrials.eg427.com\/","name":"Home - Clinical trials | EG 427","isPartOf":{"@id":"https:\/\/clinicaltrials.eg427.com\/#website"},"datePublished":"2024-10-13T10:23:03+00:00","dateModified":"2026-02-09T12:52:17+00:00","description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","breadcrumb":{"@id":"https:\/\/clinicaltrials.eg427.com\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinicaltrials.eg427.com\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clinicaltrials.eg427.com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/clinicaltrials.eg427.com\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/clinicaltrials.eg427.com\/#website","url":"https:\/\/clinicaltrials.eg427.com\/","name":"Clinical trials | EG 427","description":"","publisher":{"@id":"https:\/\/clinicaltrials.eg427.com\/#organization"},"alternateName":"Clinical trials | EG 427","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinicaltrials.eg427.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/clinicaltrials.eg427.com\/#organization","name":"Clinical trials | EG 427","alternateName":"Clinical trials","url":"https:\/\/clinicaltrials.eg427.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/clinicaltrials.eg427.com\/#\/schema\/logo\/image\/","url":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Design-6.png","contentUrl":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Design-6.png","width":804,"height":1156,"caption":"Clinical trials | EG 427"},"image":{"@id":"https:\/\/clinicaltrials.eg427.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/8","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/comments?post=8"}],"version-history":[{"count":72,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/8\/revisions"}],"predecessor-version":[{"id":335,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/8\/revisions\/335"}],"wp:attachment":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/media?parent=8"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}